MARINUS PHARMACEUTICALS INC Form 8-K April 23, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported)

April 21, 2015

MARINUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-36576 (Commission File Number) 20-0198082 (I.R.S. Employer Identification No.)

Three Radnor Corporate Center 100 Matsonford Road, Suite 304 Radnor, PA (Address of principal executive offices)

19087 (Zip Code)

Registrant s telephone number, including area code: (484) 801-4670

(Former name or former address, if changed since last report)

	the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of owing provisions:
0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

On April 21, 2015, Marinus Pharmaceuticals, Inc. (the Company) held its 2015 Annual Meeting of Stockholders. At the meeting, the stockholders voted on: (1) the election of two Class I directors and (2) the ratification of the appointment of KPMG LLP as the Company s independent registered public accounting firm for the year ending December 31, 2015. The voting results on these proposals were as follows:

Proposal 1: Election of Two Class I Directors

Director	Votes For	Withheld	Broker Non-votes
Christopher M. Cashman	7,797,907	329,787	1,484,513
Stephen Bloch, M.D.	7,797,907	329,787	1,484,513

Proposal 2: Ratification of the appointment of KPMG LLP as the Company s independent registered public accountant firm for the year ending December 31, 2015

Votes For	Votes Against	Abstentions
9,487,645	124,562	0
	2	

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARINUS PHARMACEUTICALS, INC.

By: /s/ Edward Smith

Edward Smith,

Vice President, Chief Financial Officer,

Secretary and Treasurer

Date: April 23, 2015

3